Comparison
Semaglutide vs TUDCA
Side-by-side of Semaglutide and TUDCA. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Semaglutide
Semaglutide for weight loss: GLP-1 agonist (Ozempic, Wegovy) drives 15-17% mean loss at 2.4 mg/week in STEP trials. Watch lean-mass loss.
TUDCA
TUDCA is the taurine-conjugated form of ursodeoxycholic acid, a bile-acid molecule with replicated effects on liver function, ER stress, and bile flow.
Effects at a glance
Semaglutide
- •Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
- •STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
- •Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
- •SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
- •Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
- •GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration
TUDCA
- •Bile-acid molecule (taurine-conjugated UDCA) with chemical chaperone activity at the endoplasmic reticulum
- •Established pharmaceutical use for cholestasis and primary biliary cholangitis at 500-750 mg/day
- •Reduces ER stress and stabilizes misfolded proteins; the mechanistic basis for emerging ALS / retinal applications
- •Modest improvements in NAFLD markers and insulin sensitivity at 500-1,750 mg/day in small trials
- •Mitochondrial protection signal in animal models drives the longevity-supplement positioning
- •Generally well-tolerated; mild GI effects are the main dose-dependent issue
Side-by-side
| Attribute | Semaglutide | TUDCA |
|---|---|---|
| Category | pharmaceutical | supplement |
| Also known as | Ozempic, Wegovy, Rybelsus | tauroursodeoxycholic acid, taurine-conjugated UDCA |
| Half-life (hr) ↗ | 168 | 4 |
| Typical dose (mg) ↗ | 2.4 | 500 |
| Dosing frequency | weekly (SC); daily (oral Rybelsus) | daily, divided into 2 doses with food |
| Routes | subcutaneous, oral | oral |
| Onset (hr) | 24 | 1 |
| Peak (hr) | 72 | 2 |
| Molecular weight | 4113.58 | 499.7 |
| Molecular formula | - | C26H45NO6S |
| Mechanism | Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers. | Bile-acid signaling via FXR/TGR5 receptors; chemical chaperone reducing ER stress and unfolded protein response; mitochondrial protection through reduced outer-membrane permeabilization. |
| Legal status | Prescription only (FDA-approved, EMA-approved) | OTC dietary supplement (US); pharmaceutical in Italy and several Asian countries |
| WADA status | allowed | allowed |
| DEA / Rx | Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021) | OTC supplement |
| Pregnancy | Not recommended; discontinue 2 months before planned pregnancy | Insufficient data for supplement use; UDCA used in cholestasis of pregnancy |
| CAS | 910463-68-2 | 14605-22-2 |
| PubChem CID | 56843331 | 9848818 |
| Wikidata | Q27089394 | Q418751 |
Safety profile
Semaglutide
Common side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
- fatigue
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
TUDCA
Common side effects
- mild GI upset
- diarrhea (dose-dependent)
- constipation (rare)
- nausea
Contraindications
- complete biliary obstruction
- pregnancy / lactation (insufficient supplement-dose data)
- active GI disease without medical supervision
Interactions
- cyclosporine, oral contraceptives, fat-soluble vitamins: modest absorption changes via altered bile-acid pool(minor)
- phenylbutyrate: synergistic for ALS use (Relyvrio combination); consult clinician(moderate)
Which Should You Take?
TUDCA comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Semaglutide is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Semaglutide.
- → If your priority is fat loss, pick Semaglutide.
- → If your priority is liver function, pick TUDCA.
- → If your priority is healthspan extension, pick TUDCA.
Edge case: If you want to avoid prescription-only, TUDCA is the more accessible choice.
Default choice: TUDCA. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Semaglutide only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Semaglutide and TUDCA?
Semaglutide and TUDCA differ in category (pharmaceutical vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Semaglutide or TUDCA?
Semaglutide half-life is 168 hours; TUDCA half-life is 4 hours.
Can you stack Semaglutide with TUDCA?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper